Indivior Pharmaceuticals reported a gross margin of 85.71% and a net margin of 35.57% for the quarter ended Jun 2026. These financial ratios cover 13 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2021 | Dec2022 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||
| Gross Margin | 86.62% | 73.58% | 78.50% | 83.61% | 83.08% | 82.78% | 73.25% | 81.56% | 87.38% | 85.71% | |||
| EBT Margin | 25.70% | -40.47% | 9.77% | 12.71% | 22.18% | 20.53% | 11.78% | 22.63% | 36.28% | 46.65% | |||
| EBIT Margin | 26.41% | -39.46% | 11.40% | 15.38% | 24.81% | 23.84% | 13.69% | 22.63% | 43.22% | 46.65% | |||
| EBITDA Margin | 26.41% | -39.46% | 11.40% | 15.38% | 24.81% | 23.84% | 13.69% | 22.63% | 43.22% | 46.65% | |||
| Operating Margin | 26.41% | -39.46% | 11.40% | 15.38% | 24.81% | 23.84% | 13.69% | 22.63% | 43.22% | 46.65% | |||
| Net Margin | 21.83% | -32.78% | 7.17% | 7.02% | 18.05% | 5.96% | 13.38% | 28.49% | 28.08% | 35.57% | |||
| FCF Margin | -13.73% | 28.09% | -1.63% | -11.04% | 26.32% | 46.69% | -18.79% | -68.44% | -9.15% | 64.72% | |||
| Efficiency | |||||||||||||
| Inventory AverageInventory Avg. | 104.50M | 120.00M | 165.00M | 156.00M | 152.00M | 154.00M | 152.50M | 151.00M | |||||
| Assets AverageAssets Avg. | 1,345.50M | 1,413.50M | 1,434.00M | 1,308.50M | 1,199.00M | 1,215.00M | |||||||
| Invested CapitalInvested Cap. | 366.00M | 228.00M | 59.00M | -4.00M | 44.00M | 69.00M | 115.00M | 221.00M | 342.00M | 279.00M | |||
| Asset Utilization RatioAsset Util. | 0.87 | 0.83 | 0.82 | 0.95 | 1.08 | 1.10 | |||||||
| Leverage & Solvency | |||||||||||||
| Interest Coverage RatioInterest Cover | 8.33 | -13.11 | 3.18 | 3.54 | 5.50 | 4.80 | 3.58 | 13.50 | 19.57 | 80.00 | |||
| Debt Ratio | 0.14 | 0.25 | 0.24 | 0.22 | 0.23 | 0.27 | 0.41 | 0.39 | |||||
| Times Interest Earned | 8.33 | -13.11 | 3.18 | 3.54 | 5.50 | 4.80 | 3.58 | 13.50 | 19.57 | 80.00 | |||
| Valuation | |||||||||||||
| Price to EarningsP/E | 46.99 | -22.21 | 58.50 | 73.78 | 24.77 | 102.17 | 71.67 | 43.99 | 41.75 | 39.69 | |||
| Price to SalesP/S | 10.26 | 7.28 | 4.19 | 5.18 | 4.47 | 6.09 | 9.59 | 12.53 | 11.72 | 14.12 | |||
| Price to BookP/B | 20.77 | -197.90 | -11.33 | -18.09 | -7.74 | -4.15 | -4.60 | -4.17 | -7.16 | -14.54 | -45.79 | -25.81 | -23.28 |
| Enterprise Value | 1,410.63M | 2,075.46M | 1,353.76M | 2,913.12M | 2,176.20M | 1,287.00M | 1,229.47M | 816.05M | 1,329.11M | 2,565.23M | 4,292.34M | 3,541.18M | 4,620.10M |
| EV to EBIT | 38.84 | -18.44 | 36.77 | 26.73 | 12.36 | 18.46 | 59.66 | 52.99 | 25.85 | 28.88 | |||
| EV to EBITDA | 38.84 | -18.44 | 36.77 | 26.73 | 12.36 | 18.46 | 59.66 | 52.99 | 25.85 | 28.88 | |||
| Market Capitalization | 2,512.64M | 2,968.46M | 2,084.76M | 2,913.12M | 2,176.20M | 1,287.00M | 1,549.47M | 1,189.05M | 1,839.11M | 3,010.23M | 4,487.34M | 3,716.18M | 4,842.10M |
| Price to FCFP/FCF | -74.70 | 25.91 | -257.40 | -46.95 | 16.99 | 13.04 | -51.02 | -18.32 | -128.14 | 21.81 | |||
| EV to FCF | -74.70 | 25.91 | -257.40 | -37.26 | 11.66 | 9.43 | -43.48 | -17.52 | -122.11 | 20.81 | |||
| EV to CFO | -78.73 | 24.73 | 643.50 | -72.32 | 10.88 | 8.41 | -65.78 | -19.42 | -393.46 | 20.18 | |||
| Return Ratios | |||||||||||||
| Return on Sales [ROS]ROS | 26.41% | -39.46% | 11.40% | 15.38% | 24.81% | 23.84% | 13.69% | 22.63% | 43.22% | 46.65% | |||
| Return on Capital Employed [ROCE]ROCE | 8.52% | 61.26% | 48.40% | 66.41% | 79.29% | 121.33% | |||||||
| Return on Invested Capital [ROIC]ROIC | -169.17% | 223.54% | 162.39% | 137.03% | 100.65% | 122.48% | |||||||
| Return on Assets [ROA]ROA | -0.52% | 7.71% | 9.00% | 16.05% | 20.93% | 29.22% |